Home/Monopar Therapeutics/Andrew P. Mazar, PhD
AP

Andrew P. Mazar, PhD

Chief Scientific Officer, Co-Founder, and Director

Monopar Therapeutics

Roles

Chief Scientific Officer, Co-Founder, and DirectoratMonopar Therapeutics
Chief Scientific OfficeratSera Prognostics

Monopar Therapeutics Pipeline

DrugIndicationPhase
Validive (clonidine HCl MBT)Prevention of severe oral mucositis in head and neck cancer patients receiving chemoradiotherapyPhase 2b/3
MNPR-101Advanced cancers (e.g., pancreatic, triple-negative breast cancer)Preclinical
MNPR-202 (camsirubicin)Advanced soft tissue sarcomaPhase 1b